文献速递神经免疫

法国多发性硬化患者接种COVID-19疫苗后复发风险:自身对照病例系列研究

Risk of Relapse After COVID-19 Vaccination Among Patients With Multiple Sclerosis in France: A Self-Controlled Case Series.
PubMed 文献 · Neurology · 2024-08-14

该全国性自身对照病例系列研究基于法国国家健康数据系统,纳入2021年1月1日识别的124,545例多发性硬化患者,其中82%接种至少1剂COVID-19疫苗。接种后45天内需高剂量皮质类固醇治疗的严重复发总体发生率比为0.97(0.91-1.03,p=0.30),各亚组未见风险升高;但高疾病活动度患者加强针后复发风险不能排除(IRR 1.39 [1.08-1.80])。

要点

  • 接种COVID-19疫苗后45天内严重复发总体风险未升高,IRR 0.97(0.91-1.03,p=0.30)。
  • 年龄小于50岁、病程小于10年、使用疾病修饰治疗者复发风险均未升高。
  • 高疾病活动度患者加强针后复发风险不能排除,IRR 1.39(1.08-1.80)。

核心结论

  • 几乎全部多发性硬化患者接种COVID-19疫苗后需皮质类固醇治疗的复发风险未增加,但过去2年内至少2次复发的患者加强针后风险不能排除。

研究设计与样本

  • 基于法国国家健康数据系统的全国性自身对照病例系列研究。
  • 2021年1月1日识别124,545例多发性硬化患者,截至2021年12月31日82%(n=102,524)接种至少1剂COVID-19疫苗,共259,880剂。
  • 评估接种后45天内需高剂量皮质类固醇治疗的复发风险。

主要发现

  • 总体复发发生率比IRR 0.97(0.91-1.03,p=0.30)。
  • 年龄小于50岁、病程小于10年、使用疾病修饰治疗等亚组同样无风险升高。
  • 高疾病活动度患者加强针后复发风险IRR 1.39(1.08-1.80),不能排除风险升高。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND OBJECTIVES: People with multiple sclerosis (MS) have an increased risk of severe coronavirus infection due to their level of motor disability or exposure to certain immunosuppressive treatments. Thus, patients with MS have had priority access to coronavirus disease 2019 (COVID-19) vaccination. However, relapses after vaccination have been reported, leading some patients to not seek the recommended booster doses. The main objective was to estimate the risk of severe relapse after 1, 2, and 3 (booster) doses of COVID-19 vaccination in patients with MS. The secondary objectives were to assess the risk of relapse in clinically meaningful subgroups according to the type of vaccine, the characteristics of the patients, and the use of disease-modifying treatments (DMTs). METHODS: We conducted a nationwide study using data from the French National Health Data System. Patients with MS were identified according to ICD codes, specific treatments, and reimbursement data up to March 31, 2022. Relapses requiring treatment with high-dose corticosteroids were identified. A self-controlled case series method was used to evaluate the risk of relapse associated with COVID-19 vaccines in the 45 days after vaccination. The associated risk was evaluated after 1, 2, or 3 (booster) doses and is expressed as overall incidence rate ratios (IRRs) and in subgroups of interest. RESULTS: Overall, 124,545 patients with MS were identified on January 1, 2021, and 82% received at least 1 dose of a COVID-19 vaccine (n = 102,524) until December 31, 2021, for a total of 259,880 doses. The combined IRR for MS relapse was 0.97 (0.91-1.03, p = 0.30). The same absence of risk was confirmed in various subgroups (age younger than 50 years, duration of MS < 10 years, use of DMT). A small increase in the relapse risk cannot be excluded after a booster dose (IRR 1.39 [1.08-1.80]) for patients with high MS activity, especially when not treated. DISCUSSION: There is no increased risk of relapse requiring corticosteroid therapy after COVID-19 vaccination for almost all patients. We cannot exclude an increased risk after the booster dose for patients who have had at least 2 relapses in the previous 2 years. CLASSIFICATION OF EVIDENCE: This study provides Class III evidence that COVID-19 vaccination does not increase the risk of severe relapse in patients with MS.

来源:Neurology,查看原文。版权归原作者所有。

引用

  1. Moisset X, Leray E, Chenaf C, et al. Risk of Relapse After COVID-19 Vaccination Among Patients With Multiple Sclerosis in France: A Self-Controlled Case Series. Neurology. 2024. PMID: 39141880. doi:10.1212/WNL.0000000000209662

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。